DNA Analysis of Bone Marrow and Blood Samples From Young Patients With Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying samples of bone marrow and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at DNA in bone marrow and blood samples from young patients with acute myeloid leukemia or acute lymphoblastic leukemia.

Detailed Description
-----------------
OBJECTIVES: Characterize the clinical, morphologic, immunologic, cytogenetic, and molecular heterogeneity of acute lymphoblastic leukemia or acute myeloid leukemia (AML) in infants and monoblastic variants of AML in young patients. Characterize the clinical, morphologic, immunologic, cytogenetic, and molecular heterogeneity of secondary AML in young patients. Compare secondary AML vs de novo AML at the level of Southern blot, breakpoint sequence, and DNA topoisomerase II cleavage sites. OUTLINE: This is a multicenter study. Bone marrow or blood are collected and analyzed by Southern blot for chromosome 11q23 breakpoints and translocations. Samples from patients with secondary acute myeloid leukemia are also examined for MLL gene rearrangements. PROJECTED ACCRUAL: A total of 250 patients will be accrued for this study.

Official Title
-----------------
The Molecular Epidemiology of de Novo and Treatment Related 11q23 Leukemia in the Young

Conditions
-----------------
Leukemia

Intervention / Treatment
-----------------
* Genetic: Southern blotting
* Genetic: chromosomal translocation analysis
* Genetic: cytogenetic analysis
* Genetic: gene rearrangement analysis
* Genetic: mutation analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Diagnosis of leukemia meeting 1 of the following criteria: Acute lymphoblastic leukemia OR acute myeloid leukemia (AML) (< 1 year of age at diagnosis) M4 OR M5 AML (< 5 years of age at diagnosis) Secondary leukemia (< 21 years of age at diagnosis) Bone marrow sample, peripheral blood (WBC > 10,000/mm³ and 20% peripheral blasts), or pheresis bag available PATIENT CHARACTERISTICS: Not specified PRIOR CONCURRENT THERAPY: Not specified

Ages Eligible for Study
-----------------
Maximum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All Patients<br>Completion of Telephone Study Entry Form, Additional On Study Form, and Specimen Transmittal Form. | Genetic: Southern blotting<br> <br> Genetic: chromosomal translocation analysis<br> <br> Genetic: cytogenetic analysis<br> <br> Genetic: gene rearrangement analysis<br> <br> Genetic: mutation analysis<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical, morphologic, immunologic, cytogenetic, and molecular characteristics of acute lymphoblastic leukemia and de novo and secondary acute myeloid leukemia (AML) |  |  | 
| Comparison of secondary AML vs de novo AML at the level of Southern blot, breakpoint sequence, and DNA topoisomerase II cleavage sites |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
childhood acute myelomonocytic leukemia (M4), childhood acute monocytic leukemia (M5b), childhood acute monoblastic leukemia (M5a), secondary acute myeloid leukemia, untreated childhood acute lymphoblastic leukemia, untreated childhood acute myeloid leukemia and other myeloid malignancies, recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia